Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting

Figure 3

Efficiency frontier. This plot represents the base case results in terms of quality-adjusted life years (QALYs) and costs.